The company’s research and development expenses were significantly increased over the second quarter of last year, from $468,000 to nearly $1.4 million. During this quarter, the company formed a strategic research collaboration with the Miami Project to Cure paralysis for the development of spinal chord injury treatments.
Jonathan Slotkin, MD, was also appointed medical director during this past quarter.
Read the second quarter financial report on InVivo Therapeutics.
Related Articles to Device Company Financial Reports:
TranS1 Revenues Continue to Slide in 2Q With 26% Decrease
MAKO Surgical 2Q Revenue Reaches $18.6M, 81% Increase
Alphatec Holdings Reports 2Q Revenue of $50.9M, 12% Increase
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.